Fruquintinib (FRUZAQLA)
Criteria for Use
May 2024

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the *PBM INTRAnet* site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive fruquintinib.

- ☐ Unmanageable drug-drug interaction
- ☐ Severe renal impairment (creatinine clearance < 30 mL/min)
- ☐ Baseline proteinuria (Protein of ≥2g on urinalysis/24 hours or 24-hour urine protein of ≥ 1.0g)
- ☐ Moderate or severe hepatic impairment (total bilirubin > 1.5 times the Upper Limit of Normal, unless with Gilbert syndrome)
- ☐ Uncontrolled hypertension
- ☐ Major surgery within 2 weeks or until adequate wound healing has been achieved
- ☐ Pregnancy
- ☐ Lactating

Inclusion Criteria

All of the following criteria must be met.

- ☐ Care is provided by a VA/VA Community Care oncology provider
- ☐ Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- ☐ Goals of care and role of Palliative Care consult have been discussed and documented

Additional Inclusion Criteria

Patient with diagnosis of metastatic colorectal cancer AND All of the following sub-criterion must be met

- ☐ Received prior treatment with or is not a candidate to receive a fluoropyrimidine-based regimen
- ☐ Received prior treatment with or is not a candidate to receive an oxaliplatin-based regimen
- ☐ Received prior treatment with or is not a candidate to receive an irinotecan-based regimen
- ☐ If KRAS wild type, received an anti-EGFR agent (i.e. cetuximab or panitumumab)
- ☐ Received prior treatment with or is not a candidate to receive trifluridine-tipiracil with or without bevacizumab

Additional Inclusion Criteria *(select if applicable)*

- ☐ Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for 2 weeks after the last dose.

Prepared: May 2024. Contact: Berni Heron, Pharm.D., BCOP National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)